EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Syk protein inhibitors treatment for the allergic symptoms associated with hyper immunoglobulin E syndromes: A focused on a computational approach

Mariam Mansouri iD, Ghyzlane ElHaddoumi, Ilham Kandoussi, Lahcen Belyamani, Azeddine Ibrahimi, Naima El Hafidi

International Journal of Immunopathology and Pharmacology · 2024

DOI: 10.1177/03946320241282030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2024. Verfasst von Mariam Mansouri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Biotechnology Lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University, Rabat, Morocco. Hauptthemen laut MEDLINE: Syk Kinase, Molecular Docking Simulation, Mutation, Molecular Dynamics Simulation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Mutations in the Spleen tyrosine kinase (Syk) protein have significant implications for its function and response to treatments. Understanding these mutations and identifying new inhibitors can lead to more effective therapies for conditions like autosomal dominant hyper-IgE syndrome (AD-HIES) and related immunological disorders.

Objective

To investigate the impact of mutations in the Syk protein on its function and response to reference treatments, and to explore new inhibitors tailored to the mutational profile of Syk.

Methods

We collected and analyzed mutations affecting the Syk protein to assess their functional impact. We screened 94 deleterious mutations in the kinase domain using molecular docking techniques. A library of 997 compounds with potential inhibitory activity against Syk was filtered based on Lipinski and Veber rules and toxicity assessments. We evaluated the binding affinity of reference inhibitors and 14 eligible compounds against wild-type and mutant Syk proteins. Molecular dynamics simulations were conducted to evaluate the interaction of Syk protein complexes with the reference inhibitor and potential candidate inhibitors.

Results

Among the analyzed mutations, 60.5% were identified as deleterious, underscoring their potential impact on cellular processes. Virtual screening identified three potential inhibitors (IDs: 118558008, 118558000, and 118558092) with greater therapeutic potential than reference treatments, meeting all criteria and exhibiting lower IC50 values. Ligand 1 (ID: 118558000) demonstrated the most stable binding, favorable compactness, and extensive interaction with solvents. A 3D pharmacophore model was constructed, identifying structural features common to these inhibitors.

Conclusion

This study found that 60.5% of reported mutations affecting the Syk protein are deleterious. Virtual screening revealed three top potential inhibitors, with ligand 1 (ID: 118558000) showing the most stable binding and favorable interactions. These inhibitors hold promise for more effective therapies targeting Syk-mediated signaling pathways. The pharmacophore model provides valuable insights for developing targeted therapies for AD-HIES and related disorders, offering hope for patients suffering from Hyper IgE syndrome with allergic symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Syk KinaseMolecular Docking SimulationMutationMolecular Dynamics SimulationHumansProtein Kinase InhibitorsJob Syndrome

Stichwörter der Autor:innen

3D pharmacophoreautosomal dominant hyper-IgE syndromemutational effectstargeting of Syk proteinvirtual screening

Substanzen

Syk KinaseSYK protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Biotechnology Lab (MedBiotech), Bioinova Research Center, Medical and Pharmacy School, Mohammed V University, Rabat, Morocco.
  • Mohammed VI Center of Research and Innovation (CM6), Rabat, Morocco.
  • Mohammed VI University of Health Sciences (UM6SS), Casablanca, Morocco.
  • Emergency Department, Military Hospital Mohammed V, Medical and Pharmacy School, Mohammed V University, Rabat, Morocco.
  • Division of Pediatric Immunoallergology and Infectious Diseases, Children University Hospital, Ibn Sina University, Rabat, Morocco.

ORCID-Profile: Mariam Mansouri

Zitieren

APA

Mansouri, M., ElHaddoumi, G., Kandoussi, I., Belyamani, L., Ibrahimi, A., & El Hafidi, N. (2024). Syk protein inhibitors treatment for the allergic symptoms associated with hyper immunoglobulin E syndromes: A focused on a computational approach. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320241282030

Vancouver

Mansouri M, ElHaddoumi G, Kandoussi I, Belyamani L, Ibrahimi A, El Hafidi N. Syk protein inhibitors treatment for the allergic symptoms associated with hyper immunoglobulin E syndromes: A focused on a computational approach. International Journal of Immunopathology and Pharmacology. 2024. doi:10.1177/03946320241282030

BibTeX
@article{Mansouri2024,
  author = {Mansouri, Mariam and ElHaddoumi, Ghyzlane and Kandoussi, Ilham and Belyamani, Lahcen and Ibrahimi, Azeddine and El Hafidi, Naima},
  title = {Syk protein inhibitors treatment for the allergic symptoms associated with hyper immunoglobulin E syndromes: A focused on a computational approach},
  journal = {International Journal of Immunopathology and Pharmacology},
  year = {2024},
  doi = {10.1177/03946320241282030}
}
Kostenlos starten →